Bryn Mawr Capital Management LLC Boosts Stake in Stryker Co. (NYSE:SYK)

Bryn Mawr Capital Management LLC lifted its holdings in shares of Stryker Co. (NYSE:SYK) by 0.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,970 shares of the medical technology company’s stock after purchasing an additional 39 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Stryker were worth $3,590,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Assenagon Asset Management S.A. increased its stake in shares of Stryker by 15.6% in the third quarter. Assenagon Asset Management S.A. now owns 10,304 shares of the medical technology company’s stock worth $3,722,000 after purchasing an additional 1,392 shares in the last quarter. Arkadios Wealth Advisors increased its holdings in shares of Stryker by 23.0% in the third quarter. Arkadios Wealth Advisors now owns 732 shares of the medical technology company’s stock worth $265,000 after purchasing an additional 137 shares during the period. J.W. Cole Advisors Inc. raised its position in shares of Stryker by 23.4% in the third quarter. J.W. Cole Advisors Inc. now owns 3,932 shares of the medical technology company’s stock worth $1,420,000 after buying an additional 746 shares in the last quarter. Autumn Glory Partners LLC grew its position in Stryker by 139.8% during the third quarter. Autumn Glory Partners LLC now owns 2,038 shares of the medical technology company’s stock worth $737,000 after buying an additional 1,188 shares in the last quarter. Finally, Old Port Advisors increased its stake in Stryker by 5.2% in the 3rd quarter. Old Port Advisors now owns 934 shares of the medical technology company’s stock worth $337,000 after acquiring an additional 46 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Stryker Price Performance

SYK stock opened at $390.57 on Wednesday. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The firm has a market capitalization of $149.03 billion, a price-to-earnings ratio of 50.33, a PEG ratio of 2.93 and a beta of 0.96. The firm has a 50 day moving average price of $378.78 and a 200-day moving average price of $370.22.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the previous year, the firm earned $3.46 earnings per share. Equities research analysts forecast that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s payout ratio is presently 43.30%.

Analyst Ratings Changes

A number of equities analysts have commented on SYK shares. Robert W. Baird boosted their price target on shares of Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Tuesday. UBS Group increased their target price on Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Barclays lifted their price target on Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Finally, Truist Financial increased their price objective on Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a research report on Thursday, January 30th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $422.15.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.